Background: Recently, enormous progress in cancer therapy has been achieved by the use of immune checkpoint inhibitors. Activating the body's own immune system has added a novel and powerful therapeutic option for the treatment of melanoma and lung cancer. Furthermore, the potential use of immunotherapy is being extensively explored also in other malignancies. 
.000 new cases per year worldwide. 13 In locally advanced disease, multimodal therapy is currently based on surgery, chemotherapy and radiation, while R/M HNSCC is fatal and mainly treated with palliative chemotherapy. In the primary setting, despite F I G U R E 1 Search process for immunotherapy studies using checkpoint inhibitors in HNSCC
Keypoints
• 45 relevant studies using immune checkpoint inhibitors in HNSCC were identified.
• 16 of them are using checkpoint inhibitiors as neoadjuvant/adjuvant modality for treatment with curative intent and 6 of them are using novel immune checkpoint modulators combined with the inhibition of the PD-1/PD-L1 axis or CTLA-4.
• 4 studies that use immune checkpoint inhibitiors in R/M HNSCC have presented results.
• First results of clinical trials show an evidence of improved efficacy, a favorable safety profile and an extended duration of response in favor of using immune checkpoint modulation in R/M HNSCC as compared to standard treatment.
• Preliminary data suggest that a PD-L1 expression ≥1% is associated with a higher response rate compared to a PD-L1 expression ≤1%
• A possible benefit of combined inhibition of the PD-1/ PD-L1 axis and CTLA-4 and the efficacy of treatment with curative intent have yet to be demonstrated.
all efforts, the 5-year survival rate for locally advanced disease has remained at 50%-55%. 14 Therefore, in all advanced stages of the disease there is a great need to improve treatment efficacy and immunotherapy is believed to become an important additional modality in the near future.
While the main interest and research efforts in HNSCC immunotherapy currently concentrate on PD-1 and CTLA-4 inhibition, other promising targets are also being evaluated. In Table 1 , we summarise the immunomodulatory therapeutics tested in the current studies, together with their respective target receptors.
| METHODS
This review was conducted according to the PRISMA guidelines. A search from 2010 onwards using the key terms "checkpoint inhibition head and neck cancer," "checkpoint inhibitors head and neck cancer,"
"PD-1 inhibitor head and neck cancer," PD-1 head and neck cancer,"
"CTLA-4 inhibitor head and neck cancer," "CTLA-4 head and neck cancer," "pembrolizumab head and neck cancer," "nivolumab head and neck cancer," "ipilimumab head and neck cancer," "MEDI4736 head 15 and an expansion cohort of patients recruited regardless of PD-L1 status. 16 The primary endpoint was the overall response rate (ORR) 
NCT

| Running studies in HNSCC without results
Numerous phase I-III studies investigating inhibitors of the PD-1/
PD-L1 axis and/or CTLA-4 are being initiated or are already running.
Currently, 16 of these trials explore the efficacy of such agents in the curative setting, while the majority investigates their application in the setting of R/M disease. In Table 3 , these studies are pre- 
NCT02841748
A total of 100 patients with HNSCC at high risk for recurrence will be recruited in this randomized double-blind phase 2 trial for adjuvant pembrolizumab vs placebo after completed curative intent therapy. Pembrolizumab 200 mg or a placebo will be administered every 3 weeks up to 1 year to evaluate PFS. 
|
nct02551159 (kestrel)
In this three-arm phase III trial, 628 patients who have not received prior systemic chemotherapy for R/M disease will be randomized in a ratio 2:1:1 to durvalumab monotherapy (1500 mg every 4 weeks), durvalumab in combination with tremelimumab (75 mg every 4 weeks for 4 cycles) and SoC treatment. Tumour tissue samples will be investigated for PD-L1 status (cut-off≥25%). Co-primary objectives will be to assess the efficacy of durvalumab alone and the combination of durvalumab and tremelimumab compared to SoC in terms of PFS and OS.
Secondary endpoint is, among others, the ORR. Table 4 . For example, in NCT02221960 OX40 stimulation (agonistic anti-OX40-antibody MEDI6383) will be applied alone or in combination with durvalumab and in NCT02335918 varlilumab, an agonistic anti-CD27 antibody, will be combined with nivolumab. Both trials intend to evaluate the safety, tolerability and antitumour activity of both stimulatory-acting checkpoint modulators.
| DISCUSSION
Recently, the first results of clinical trials using PD-1/PD-L1 immune checkpoint inhibitors in patients with R/M HNSCC have demonstrated both a survival benefit and a favourable safety profile in favour of immune checkpoint inhibition as compared to standard treatment. 15, 16, 18, 20, 21, 27 In particular, an extended duration of response for patients who initially responded has been reported, which has recently led to the accelerated approval of pembrolizumab for R/M HNSCC in the US.
However, it remains to be shown whether immune checkpoint inhibitors can be practice changing similar to the situation in melanoma and lung cancer and whether it will become standard of care as first-line therapy in the palliative setting in HNSCC. Recently, the with PD-L1 expression remain to be shown in the future when more data will be available.
In summary, the preliminary data reported so far indicate that monotherapeutic inhibition of the PD-1/PD-L1 axis may be superior to current SoC treatment, especially in terms of long-term responses.
Despite these encouraging data, the need to improve the currently low overall response rates remains. In this regard, a possible option might be the combined inhibition of the PD-1/PD-L1 axis and CTLA-4; however, the efficacy and the safety of this double targeting approach still remain to be demonstrated in R/M HNSCC through the initiated studies.
While PD-1/PD-L1 and CTLA-4 govern the most prominent immune pathways, antibodies targeting other inhibitory receptors but also antibodies activating stimulatory immune receptors are already being investigated in phases I and II studies (Table 4) 
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